Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

Tempest Therapeutics, Inc. (TPST) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

Tempest Therapeutics, Inc. (TPST), most recent 12 months reported: net loss $40.47M, free cash flow -$20.73M. Latest balance sheet on file: liquid cash $779K. From SEC filings. Others in Pharmaceutical Preparations: Spyre Therapeutics, Inc. · Telomir Pharmaceuticals, Inc. · TENAX THERAPEUTICS, INC. · Theriva Biologics, Inc. · TRAFALGAR INTERNATIONAL, INC. · Trevi Therapeutics, Inc. · Turn Therapeutics Inc. · TVARDI THERAPEUTICS, INC.

Stock screener

Watchlist